<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02979873</url>
  </required_header>
  <id_info>
    <org_study_id>170019</org_study_id>
    <secondary_id>17-H-0019</secondary_id>
    <nct_id>NCT02979873</nct_id>
  </id_info>
  <brief_title>Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy</brief_title>
  <official_title>A Randomized Trial of Sirolimus (Rapamune(R)) for Relapse Prevention in Patients With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or&#xD;
      platelets. Their body's immune system stops the bone marrow from making these cells. The&#xD;
      treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the&#xD;
      disease may return in 1 in 3 people. The drug sirolimus may help by suppressing the immune&#xD;
      system.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To evaluate and compare the usefulness of sirolimus in preventing aplastic anemia from&#xD;
      returning after cyclosporine is stopped, compared with stopping cyclosporine alone.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      People ages 2 and older with SAA who:&#xD;
&#xD;
      Have responded to immunosuppressive therapy that includes cyclosporine, and continue to take&#xD;
      cyclosporine&#xD;
&#xD;
      Are not taking drugs with hematologic effects&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with:&#xD;
&#xD;
      Medical history&#xD;
&#xD;
      Physical exam&#xD;
&#xD;
      Blood and urine tests&#xD;
&#xD;
      Bone marrow biopsy: The area above the hipbone will be numbed. A thin needle will remove&#xD;
&#xD;
      some bone marrow.&#xD;
&#xD;
      Participants will be randomly assigned to a group. All will stop cyclosporine. Group 1 will&#xD;
      take sirolimus by mouth at the same time each day for 3 months with close monitoring. Group 2&#xD;
      will not receive the study drug but will be monitored closely.&#xD;
&#xD;
      Participants will have clinical tests for the first 3 months:&#xD;
&#xD;
      Weekly blood test&#xD;
&#xD;
      Monthly fasting blood test&#xD;
&#xD;
      For group 1, measurements of sirolimus in the blood every 1 2 weeks&#xD;
&#xD;
      Participants will have clinic visits at 3 months, 12 months, and annually for 5 years after&#xD;
      the study starts. They may have another visit if their SAA returns. These will include:&#xD;
&#xD;
      Blood and urine tests&#xD;
&#xD;
      Bone marrow biopsy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Most acquired aplastic anemia ensues from immune-mediated destruction of hematopoietic&#xD;
           stem and progenitor cells.&#xD;
&#xD;
        -  Immunosuppression is the definitive treatment of patients with acquired aplastic anemia&#xD;
           who are not candidates for immediate hematopoietic stem cell transplantation.&#xD;
&#xD;
        -  Horse ATG combined with the calcineurin inhibitor, cyclosporine (CsA), remains standard&#xD;
           as first-line immunosuppressive therapy (IST).&#xD;
&#xD;
        -  Hematologic responses to transfusion independence occur in about two thirds of patients&#xD;
           with standard IST and in 80-90% of patients treated with IST in combination with the&#xD;
           growth factor eltrombopag.&#xD;
&#xD;
        -  About 30% to 40% of patients relapse after discontinuation of cyclosporine.Many achieve&#xD;
           disease control after the reinitiation of CSA, but remain CSA dependent indefinitely.&#xD;
&#xD;
        -  Evidence from mouse models of bone marrow failure indicates that conversion from&#xD;
           cyclosporine to the mTOR inhibitor, sirolimus (SRL), results in immune tolerance which&#xD;
           can endure the eventual withdrawal of SRL.&#xD;
&#xD;
        -  We hypothesize that CSA to SRL conversion will significantly decrease the relapse rate&#xD;
           after immunosuppressive therapy for acquired aplastic anemia.&#xD;
&#xD;
        -  This study will investigate the safety and efficacy of SRL for preventing relapse in&#xD;
           patients -previously treated with IST who remain on CSA. The primary endpoint is rate of&#xD;
           relapse at 2 years following conversion from CSA to SRL, versus stopping CSA.&#xD;
&#xD;
        -  Biological sampling of peripheral blood and bone marrow aspirates during treatment will&#xD;
           be used to investigate changes to lymphocyte phenotypes and cytokine profiles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if the rate of relapse at 24 months after CSA discontinuation can be improved by conversion to sirolimus in severe aplastic anemia patients who have responded to IST.</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of relapse in both arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of sirolimus.</measure>
    <time_frame>3 mo</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).</description>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Age greater than or equal to 2 years old&#xD;
&#xD;
               2. Weight greater than 12 kg&#xD;
&#xD;
               3. Previous diagnosis of SAA by bone marrow biopsy and cytogenetics, treated with&#xD;
                  lymphodepleting therapy ATG, cyclophosphamide or alemtuzumab that included&#xD;
                  cyclosporine. The lymphodepleting therapy must have been administered at least 12&#xD;
                  months prior.&#xD;
&#xD;
               4. Continuous treatment with cyclosporine for the previous 6 months (excluding minor&#xD;
                  dose delays not exceeding more than 30 days).&#xD;
&#xD;
               5. Evidence of a hematologic response to an lymphodepletion-based regimen as&#xD;
                  evidence of at least two of the following:&#xD;
&#xD;
          -  Absolute neutrophil count greater than or equal to 500/uL&#xD;
&#xD;
          -  Platelet count greater than or equal to 20,000/uL (without transfusion support)&#xD;
&#xD;
          -  Absolute reticulocyte count greater than or equal to 60,000/uL (or hemoglobin 10 gm/dL&#xD;
             without transfusion support)&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Evidence of relapse of aplastic anemia due to cyclosporine withdrawal during the&#xD;
             previous 6 months&#xD;
&#xD;
          2. Prior use of sirolimus or other mTOR inhibitor within 12 weeks of study entry&#xD;
&#xD;
          3. Myelodysplastic syndrome or acute myeloid leukemia, according to WHO diagnostic&#xD;
             criteria (if baseline BM consistent with MDS after enrollment, patients will be&#xD;
             considered ineligible and immediately exit the study, and the subject can be replaced&#xD;
             with another subject)&#xD;
&#xD;
          4. Patients that are on CYP3A4 inhibitors and cannot replace these medications with other&#xD;
             equivalent medications for the period of study: protease inhibitors (ritonavir,&#xD;
             indinavir, nelfinavir, saquinavir), some macrolide antibiotics (clarithromycin,&#xD;
             telithromycin, erythromycin), azole anti-fungals (fluconazole, itraconazole,&#xD;
             ketoconazole), metroclopramide, felodipine, nifedipine, carbamazepine, phenobarbital,&#xD;
             grapefruit juice and St. John s Wort.&#xD;
&#xD;
          5. Anaphylactic or hypersensitivity reaction to sirolimus&#xD;
&#xD;
          6. Patients with infections not adequately responding to appropriate therapy as evidenced&#xD;
             by persistence of a clear source of infection that, in the view of the investigator,&#xD;
             would preclude safe treatment with sirolimus.&#xD;
&#xD;
          7. Current pregnancy, or unwillingness to take oral contraceptives or use the barrier&#xD;
             methods of birth control or practice abstinence to refrain from pregnancy if of&#xD;
             childbearing potential during the course of the study 8. Lactating women, due to the&#xD;
             potentially harmful effects on the nursing child.&#xD;
&#xD;
        9. Patients who have received live vaccines within the past 30 days&#xD;
&#xD;
        10. Patients with cancer who are actively receiving chemotherapeutic treatment or who take&#xD;
        drugs with hematological effects such as thrombopoietin receptor agonists (such as&#xD;
        eltrombopag), granulocyte-colony stimulating factor or erythroid stimulating agents.&#xD;
&#xD;
        11. Moribund status such that death within 7 to 10 days is likely. Comorbidities of such&#xD;
        severity that in the view of the Investigator it would likely preclude the patient's&#xD;
        ability to tolerate sirolimus.&#xD;
&#xD;
        12. Inability to understand the investigational nature of the study or to give informed&#xD;
        consent or without a legally authorized representative or surrogate that can provide&#xD;
        informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhavisha A Patel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivana Darden, R.N.</last_name>
    <phone>(301) 827-2988</phone>
    <email>ivana.darden@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bhavisha A Patel, M.D.</last_name>
    <phone>(301) 402-3477</phone>
    <email>bhavisha.patel@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2017-H-0019.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>August 30, 2023</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>September 14, 2023</last_update_submitted>
  <last_update_submitted_qc>September 14, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rapamycin</keyword>
  <keyword>Relapse Prevention</keyword>
  <keyword>Immune Tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>.This is a new requirement and the sharing of IPD is not discussed in the protocol.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02979873
org study id: 170019
secondary id: 17-H-0019
nct id: NCT02979873
lead sponsor: 
is fda regulated drug: Yes
is fda regulated device: No
Background:

      People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or
      platelets. Their body's immune system stops the bone marrow from making these cells. The
      treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the
      disease may return in 1 in 3 people. The drug sirolimus may help by suppressing the immune
      system.

      Objective:

      To evaluate and compare the usefulness of sirolimus in preventing aplastic anemia from
      returning after cyclosporine is stopped, compared with stopping cyclosporine alone.

      Eligibility:

      People ages 2 and older with SAA who:

      Have responded to immunosuppressive therapy that includes cyclosporine, and continue to take
      cyclosporine

      Are not taking drugs with hematologic effects

      Design:

      Participants will be screened with:

      Medical history

      Physical exam

      Blood and urine tests

      Bone marrow biopsy: The area above the hipbone will be numbed. A thin needle will remove

      some bone marrow.

      Participants will be randomly assigned to a group. All will stop cyclosporine. Group 1 will
      take sirolimus by mouth at the same time each day for 3 months with close monitoring. Group 2
      will not receive the study drug but will be monitored closely.

      Participants will have clinical tests for the first 3 months:

      Weekly blood test

      Monthly fasting blood test

      For group 1, measurements of sirolimus in the blood every 1 2 weeks

      Participants will have clinic visits at 3 months, 12 months, and annually for 5 years after
      the study starts. They may have another visit if their SAA returns. These will include:

      Blood and urine tests

      Bone marrow biopsy
-  Most acquired aplastic anemia ensues from immune-mediated destruction of hematopoietic
           stem and progenitor cells.

        -  Immunosuppression is the definitive treatment of patients with acquired aplastic anemia
           who are not candidates for immediate hematopoietic stem cell transplantation.

        -  Horse ATG combined with the calcineurin inhibitor, cyclosporine (CsA), remains standard
           as first-line immunosuppressive therapy (IST).

        -  Hematologic responses to transfusion independence occur in about two thirds of patients
           with standard IST and in 80-90% of patients treated with IST in combination with the
           growth factor eltrombopag.

        -  About 30% to 40% of patients relapse after discontinuation of cyclosporine.Many achieve
           disease control after the reinitiation of CSA, but remain CSA dependent indefinitely.

        -  Evidence from mouse models of bone marrow failure indicates that conversion from
           cyclosporine to the mTOR inhibitor, sirolimus (SRL), results in immune tolerance which
           can endure the eventual withdrawal of SRL.

        -  We hypothesize that CSA to SRL conversion will significantly decrease the relapse rate
           after immunosuppressive therapy for acquired aplastic anemia.

        -  This study will investigate the safety and efficacy of SRL for preventing relapse in
           patients -previously treated with IST who remain on CSA. The primary endpoint is rate of
           relapse at 2 years following conversion from CSA to SRL, versus stopping CSA.

        -  Biological sampling of peripheral blood and bone marrow aspirates during treatment will
           be used to investigate changes to lymphocyte phenotypes and cytokine profiles.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: To determine if the rate of relapse at 24 months after CSA discontinuation can be improved by conversion to sirolimus in severe aplastic anemia patients who have responded to IST.
time frame: 24 months
description: Rate of relapse in both arms
measure: Safety and tolerability of sirolimus.
time frame: 3 mo
arm group label: Sirolimus
arm group type: Experimental
description: sirolimus
arm group label: Standard of Care
arm group type: No Intervention
description: no intervention
intervention type: Drug
intervention name: Sirolimus
description: Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
arm group label: Sirolimus
criteria: 
gender: All
minimum age: 2 Years
maximum age: 99 Years
healthy volunteers: No
last name: Bhavisha A Patel, M.D.
role: Principal Investigator
affiliation: National Heart, Lung, and Blood Institute (NHLBI)
last name: Ivana Darden, R.N.
phone: (301) 827-2988
email: ivana.darden@nih.gov
last name: Bhavisha A Patel, M.D.
phone: (301) 402-3477
email: bhavisha.patel@nih.gov
facility: 
status: Recruiting
contact: 
country: United States
url: https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2017-H-0019.html
description: NIH Clinical Center Detailed Web Page
responsible party type: Sponsor
mesh term: Anemia
mesh term: Anemia, Aplastic
mesh term: Recurrence
mesh term: Sirolimus
sharing ipd: Undecided
ipd description: .This is a new requirement and the sharing of IPD is not discussed in the protocol.